Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Experts call on Canada to use COVAX doses of AstraZeneca or give them back

05/14/2021 | 05:32pm EDT

OTTAWA — Some health experts are questioning Canada's decision to accept thousands of doses of the Oxford-AstraZeneca vaccine from a global vaccine-sharing alliance, only to have them sit in freezers in an Ontario warehouse.

More than 655,000 doses of AstraZeneca arrived in Canada through the COVAX initiative Thursday even as most provinces have temporarily paused their use for first doses amid supply issues and the potential risk of rare blood clots.

It is the first time vaccines have been delivered to Canada without immediately being distributed to provinces and territories, because Ottawa isn't yet clear who wants them.

"Depending on how and when the provinces want to use them, they can either have them all now, have them on a scheduled delivery, we can hold (them) for a couple of weeks," said Maj. Gen. Dany Fortin at a vaccine briefing Thursday.

As of May 8, 2.16 million Canadians had been given one dose of AstraZeneca. With enough Pfizer-BioNTech and Moderna coming to vaccinate everyone who hasn't yet been given a first dose, the main use of AstraZeneca in Canada going forward would be for second doses.

But even that is in doubt, as a United Kingdom study looking at mixing and matching vaccines might indicate the second dose should be Pfizer or Moderna. Preliminary data this week showed doing so was safe, but how effective it was to mix them won't be known until June.

Health Minister Patty Hajdu defended accepting the doses even though they were going to be stored for now, saying there's no indication yet provinces won't use them for second doses.

"Obviously, we're monitoring this very closely, and my expectation is that doses of vaccine, regardless of the variety and type, don't go to waste," she said.

Fortin said he is preparing advice to cabinet on what to do with the doses that aren't immediately wanted but wouldn't go into detail.

"There are a range of options that we continue to investigate, the contingencies and a number of things to include what we would do with future doses," he said.

Dr. Irfan Dhalla, an internal medicine specialist in Toronto, said Canada needs to make those decisions immediately.

"We should definitely not be keeping doses of the AstraZeneca vaccine in freezers while thousands of people are dying every day in India, and other countries around the world and are desperate to receive a highly effective vaccine," he said.

Canada has been criticized before for being the only G7 country taking doses from COVAX, which was designed as a vehicle for wealthier nations to help low and middle-income nations get access to COVID-19 vaccines. Prime Minister Justin Trudeau has defended the practice, saying COVAX was designed as a way to both buy and share doses and Canada is doing nothing wrong.

Dhalla said in an ideal world vaccinations would happen equally everywhere, but he said practically that was never going to happen.

"We know that high-income countries are going to vaccinate more quickly than low-income countries," he said. "But it is unconscionable to then not use the vaccine that we have. Either we use it, or we send it to places where it can be used and we need to do that now."

NDP health critic Don Davies said Canada needs to return the COVAX doses immediately.

"When they first decided to do it there was an immediate reaction from all sorts of sources," he said. "It didn't make sense then and it's case closed now."

Dr. Alan Bernstein, the president of the global research organization CIFAR and a member of Canada's national vaccine task force, said it might make practical sense to wait until the second-dose question is answered by the U.K. study.

"I think that we wouldn't want to be caught with having given away doses (if) we ultimately will regret that literally two or three weeks later," he said.

But Bernstein said as soon as that data comes in, the decision must be made, and then if we aren't using the doses, they need to be given back to COVAX immediately.

This report by The Canadian Press was first published May 14, 2021.

© 2021 The Canadian Press. All rights reserved., source Canadian Press DataFile

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.69% 8339 Delayed Quote.13.87%
MODERNA, INC. 0.85% 218.85 Delayed Quote.109.49%
All news about ASTRAZENECA PLC
08:49aASTRAZENECA  : shots have good risk-benefit profile for over 60s, says EMA offic..
RE
05:48aASTRAZENECA  : Germany demands that J&J make up COVID-19 vaccine gap in July
RE
05:18aASPEN PHARMACARE  : South African health inspectors will not release unsuitable ..
RE
06/12CP NEWSALERT : Ontario shortens wait time for second shot after AstraZeneca vacc..
AQ
06/11ASTRAZENECA  : COVID-19 hot spot mayors want shorter dose interval for AstraZene..
AQ
06/11FDA Approves Export of Covid-19 Vaccine Doses From Troubled Baltimore Plan --..
DJ
06/11ASTRAZENECA  : U.S. FDA asks J&J to discard millions of COVID-19 vaccine doses
RE
06/11FDA Approves Export of Covid-19 Vaccine Doses from Troubled Baltimore Plant
DJ
06/11Drug Experts Explore Mixing COVID-19 Jabs Despite Side Effect Risks
MT
06/11"WE NEED MORE" : UN joins criticism of G7 vaccine pledge
RE
More news
Financials (USD)
Sales 2021 31 008 M - -
Net income 2021 4 562 M - -
Net Debt 2021 10 731 M - -
P/E ratio 2021 33,9x
Yield 2021 2,42%
Capitalization 154 B 154 B -
EV / Sales 2021 5,33x
EV / Sales 2022 4,67x
Nbr of Employees 76 100
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 132,38 $
Last Close Price 117,64 $
Spread / Highest target 45,3%
Spread / Average Target 12,5%
Spread / Lowest Target -18,2%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC13.87%154 435
JOHNSON & JOHNSON4.82%434 405
ROCHE HOLDING AG10.68%328 612
PFIZER, INC.9.07%224 747
NOVARTIS AG-0.39%208 035
ABBVIE INC.7.72%203 857